AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02735317
Drug: Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
Trial: NCT00534846
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
Trial: NCT02752308
Drug: Dilute epinephrine injection
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 1/100000 epinephrine solution along all incision lines
Trial: NCT02752308
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
Trial: NCT01654575
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 25mg/week for 16 weeks
Trial: NCT01654575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once a week for 16 weeks
Trial: NCT04056130
Drug: KBL697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral
Trial: NCT04056130
Drug: KBL697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral
Trial: NCT04056130
Drug: KBL697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral
Trial: NCT03946306
Drug: 5,25% NaOCl with syringe needle irrigation alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
Trial: NCT00683553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV injection of saline
Trial: NCT04691856
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Trial: NCT02114203
Drug: placebo for PDE9i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose, every 12 hours for 28 days
Trial: NCT02114203
Drug: PDE9i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose, every 12 hours for 28 days
Trial: NCT01518699
Drug: Ha44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abametapir Lotion 0.74%
Trial: NCT01518699
Drug: Ha44 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ha44 Vehicle Gel without Abametapir
Trial: NCT04691856
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Trial: NCT04291300
Drug: Lutetium-177-PSMA-I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
Trial: NCT01225263
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin, 20 mg, twice daily for 6 months
Trial: NCT04724486
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage adjustment according to the ovarian response.
Trial: NCT03947879
Drug: L-glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of L-glutamine twice daily by mouth for 3 months.
Trial: NCT04762355
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-to-match palovarotene ophthalmic solution vials
Trial: NCT01197573
Drug: rTPA Treatment
RxNorm normalized name: Sportpac Coldpac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
Trial: NCT01009463
Drug: FF/GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
Trial: NCT01009463
Drug: GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
Trial: NCT02413255
Drug: TAK-020 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-020 placebo-matching oral solution
Trial: NCT01742221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single subcutaneous dose
Trial: NCT00619541
Drug: Infusional 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
Trial: NCT01477632
Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 2 tablets under fasting conditions
Trial: NCT01477632
Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 1 tablet under fasting conditions
Trial: NCT01469923
Drug: AZD2820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
Trial: NCT01469923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
Trial: NCT00006669
Drug: EPOCH regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006669
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006669
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01374581
Drug: Quinine + Clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily
Trial: NCT02635438
Drug: Unique Pharmaceutical Laboratories, India
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
Trial: NCT02635438
Drug: Roxane Laboratories Inc., USA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
Trial: NCT03074006
Drug: TEW-7197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg tablets (doses will be determined through dose-escalation part)
Trial: NCT00968617
Drug: MK2578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK2578 1.0 mcg/kg/month
Trial: NCT00968617
Drug: MK2578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK2578 2.0 mcg/kg/month
Trial: NCT00968617
Drug: MK2578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK2578 3.6 mcg/kg/month
Trial: NCT01616615
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule / day oral use
Trial: NCT01878006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01790061
Drug: Traditional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications
Trial: NCT01569204
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01569204
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00402350
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Placebo, same number of doses as active comparator in that arm
Trial: NCT00402350
Drug: Inhaled Fentanyl 25 mcg
RxNorm normalized name: fentanyl Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 1 dose
Trial: NCT00402350
Drug: Intravenous Fentanyl 25 mcg
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Fentanyl 25 mcg, single dose
Trial: NCT00402350
Drug: Inhaled Fentanyl 25 mcg x 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 2 doses
Trial: NCT00402350
Drug: Inhaled Fentanyl 25 mcg x 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 4 doses
Trial: NCT00402350
Drug: Inhaled Fentanyl 25 mcg x 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 6 doses
Trial: NCT00402350
Drug: Inhaled Fentanyl 25 mcg x 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Fentanyl, 25 mcg x 12 doses
Trial: NCT01842893
Drug: Fentanyl Ethypharm
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
Trial: NCT04164212
Drug: Flumist Quadrivalent Nasal Product
RxNorm normalized name: FluMist Quadrivalent 2021-2022 Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
Trial: NCT01011205
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus
Trial: NCT02061007
Drug: Optional 18F-FMISO PET scan (18F-fluoromisonidazole)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
Trial: NCT00537823
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00537823
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00779038
Drug: Fentanyl ITS
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
Trial: NCT02225886
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
Trial: NCT02971696
Drug: Best Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver Support, pain management
Trial: NCT01192763
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04407507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
Trial: NCT02958163
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
Trial: NCT01731691
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
Trial: NCT01645280
Drug: Placebo + methotrexate (MTX) (Group 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
Trial: NCT02723162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT02601885
Drug: ABT-555
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT03576677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group.
Trial: NCT02924753
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
Trial: NCT04046484
Drug: PMZ-1620 along with standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Trial: NCT02371369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matching pexidartinib capsule for oral administration
Trial: NCT03607383
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
Trial: NCT00463450
Drug: Gynodian® Depot (BAY86-5032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection monthly
Trial: NCT00463450
Drug: BAY86-4980
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally
Trial: NCT00733265
Drug: AZD6140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT02477865
Drug: PEX168(100µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100µg,Subcutaneous injection,once a week. continued for 52 weeks
Trial: NCT02477865
Drug: PEX168(200µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200µg,Subcutaneous injection,once a week. continued for 52 weeks
Trial: NCT02477865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
Trial: NCT04039828
Drug: Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)
RxNorm normalized name: zinc sulfate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for \> 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
Trial: NCT00658333
Drug: Enteric-coated Mycophenolate Acid (EC-MPA)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04568174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
Trial: NCT01275248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet to match the experimental interventions
Trial: NCT02137629
Drug: Vidaza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
Trial: NCT03021187
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
Trial: NCT03658720
Drug: 200 mg Ibuprofen acid orodispersible tablet
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orodispersible tablet
Trial: NCT02946294
Drug: Bupivacaine 0.25% with epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01914133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given prior to meal the standardized meal
Trial: NCT00083824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills/day QID for 3 years
Trial: NCT03466346
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
Trial: NCT04592692
Drug: PEGylated Liposome (PEGLip)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous co-administration of PEGLip with Simoctocog alfa
Trial: NCT01964365
Drug: Cresto 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, rosuvastatin 20mg
Trial: NCT01112215
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
Trial: NCT01112215
Drug: Enteric-Coated Mycophenolate Sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
Trial: NCT01094483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00206518
Drug: Adriamycin/Cytoxan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin/Cytoxan
Trial: NCT00206518
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
Trial: NCT00077233
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT02697240
Drug: Intravenous citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
Trial: NCT00148590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
Trial: NCT02575664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch
Trial: NCT00642616
Drug: Technosphere® Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
Trial: NCT00642616
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
Trial: NCT01696877
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.